China Meheco Group Co.,Ltd.(600056),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600056 China Meheco Group Co.,Ltd.

Closed 03-31 15:00:00

10.46

-0.23

-2.15%

High10.65	Low10.43	Vol13.28M
Open10.61	D1 Closing10.69	Amplitude2.06%
Mkt Cap15.65B	Tradable Cap15.64B	Total Shares1.50B
T/O140.00M	T/O Rate0.89%	Tradable Shares1.50B
P/B1.34	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

暂无数据

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"China Meheco Group Co.,Ltd.","latestPrice":10.46,"timestamp":1743404400000,"preClose":10.69,"halted":0,"volume":13278775,"delay":0,"changeRate":-0.0215,"floatShares":1495000000,"shares":1496000000,"eps":0.6024,"marketStatus":"Closed","change":-0.23,"latestTime":"03-31 15:00:00","open":10.61,"high":10.65,"low":10.43,"amount":140000000,"amplitude":0.0206,"askPrice":10.47,"askSize":499,"bidPrice":10.46,"bidSize":589,"shortable":0,"etf":0,"ttmEps":0.6024,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743471000000},"marketStatusCode":5,"adr":0,"adjPreClose":10.69,"symbolType":"stock","openAndCloseTimeList":[[1743384600000,1743391800000],[1743397200000,1743404400000]],"highLimit":11.76,"lowLimit":9.62,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.34,"roa":"--","peRate":17.363878,"roe":"3.83%","epsLYR":0.7006,"committee":0.572443,"marketValue":15647000000,"turnoverRate":0.0089,"status":1,"floatMarketCap":15641000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2518753417","title":"Meheco Unit's Tranexamic Acid Injection Passes Regulatory Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2518753417","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518753417?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 11:24","pubTimestamp":1741663447,"startTime":"0","endTime":"0","summary":"China Meheco Group's  unit, China National Pharmaceutical and Healthcare Industry, received the Chinese drug administration's approval on its supplementary application for tranexamic acid injection after the drug passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange disclosure on Tuesday.The evaluation tested the efficacy and quality of the drug, which is mainly used for acute or chronic, localized or systemic primary fibrosis, the pharmaceutical company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0082","BK0028","BK0175","BK0250","BK0188","BK0010","600056","BK0185"],"gpt_icon":0},{"id":"2516859611","title":"Meheco's Unit Gets Nod to Market Sacubitril-Valsartan Sodium Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516859611","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516859611?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 13:01","pubTimestamp":1741064480,"startTime":"0","endTime":"0","summary":"The Chinese drug administration handed two drug registration certificates to China Meheco Group's  subsidiary, China National Pharmaceutical and Healthcare Industry, for sacubitril-valsartan sodium tablets, according to a Shanghai Stock Exchange filing on Tuesday.The certificates allow the company to market 50 milligrams and 100 milligrams of the anti-heart failure drug, the drugmaker said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0185","BK0175","BK0250","BK0010","BK0082","BK0188","600056"],"gpt_icon":0},{"id":"2503759680","title":"Meheco Unit's Flumazenil Injection Passes Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2503759680","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503759680?lang=en_us&edition=full_marsco","pubTime":"2025-01-14 11:44","pubTimestamp":1736826280,"startTime":"0","endTime":"0","summary":"The Chinese drug administration approved the supplementary application of China Meheco Group's  unit, Hainan General Kangli Pharmaceutical, for flumazenil injection after passing a consistency evaluation, according to a Shanghai Stock Exchange disclosure on Tuesday.The evaluation tested the drug's quality and efficacy.The drug is mainly used to reverse the central nervous system sedation caused by benzodiazepines, the pharmaceutical company said.The company's shares rose less than 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","600056","BK0250","BK0185","BK0188","BK0082","BK0028","BK0175"],"gpt_icon":0},{"id":"2493864797","title":"Meheco Unit's Angina Tablets Passes Chinese Drug Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2493864797","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493864797?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 14:40","pubTimestamp":1734936021,"startTime":"0","endTime":"0","summary":"The Chinese drug administration approved the supplementary application of China Meheco Group's  unit, China National Pharmaceutical and Healthcare Industry, for nicorandil tablets after it passed the regulator's quality and efficacy consistency evaluation.The pharmaceutical company invested 12.8 million yuan into the development of the drug, which is used to treat angina pectoris, according to a Shanghai Stock Exchange disclosure on Saturday.Meheco's shares dropped 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0250","600056","BK0185","BK0082","BK0010","BK0175","BK0188","BK0028"],"gpt_icon":0},{"id":"2491763641","title":"Meheco Unit's Sepsis Drug Included in China's Centralized Procurement Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2491763641","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491763641?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 13:01","pubTimestamp":1734325310,"startTime":"0","endTime":"0","summary":"A drug of Hainan General Sanyo Pharmaceutical, a unit of China Meheco Group , is expected to be selected in China's centralized drug procurement bid after being included in the list, according to a Shanghai Stock Exchange disclosure on Saturday.The drug, piperacillin sodium for injection, is used to treat patients with sepsis and other bodily infections. The pharmaceutical company proposed a bid of 2.27 yuan per piece for the drug.Drugs selected in the centralized bidding will be prioritized by medical institutions in the country during the procurement cycle, the disclosure said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600056"],"gpt_icon":0},{"id":"2489488846","title":"Meheco Receives Nod for Influenza Drug's Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2489488846","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489488846?lang=en_us&edition=full_marsco","pubTime":"2024-12-05 14:41","pubTimestamp":1733380876,"startTime":"0","endTime":"0","summary":"China Meheco Group  received a drug registration certificate for oseltamivir phosphate capsules from the Chinese drug administration, according to a Shanghai Stock Exchange filing on Thursday.The drug is mainly used to treat influenza A and B in adults and children, the pharmaceutical company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0250","BK0028","BK0185","BK0188","BK0010","600056","BK0082","BK0175"],"gpt_icon":0},{"id":"2488969259","title":"Meheco Gets Supplementary Drug Approval for ADHD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488969259","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488969259?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 15:30","pubTimestamp":1733211039,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Meheco (SHA:600056) two supplementary drug approvals for its atomoxetine hydrochloride capsules, according to a Tuesday filing with the Shanghai Stock Ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","ABVC","600056","ADHD","BK0175","BK4139","BK0185","BK0188","BK0082","BK0028","BK0250"],"gpt_icon":0},{"id":"2488624829","title":"China Meheco Gets Approval for Brain Trauma Surgery Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488624829","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488624829?lang=en_us&edition=full_marsco","pubTime":"2024-12-02 18:09","pubTimestamp":1733134170,"startTime":"0","endTime":"0","summary":"China's medical products administrator approved China Meheco's  supplementary drug application for citicoline sodium injection, according to a Saturday filing with the Shanghai Stock Exchange.The drug helps improve cell metabolism in acute craniocerebral trauma and consciousness disorders following brain surgery, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0185","600056","BK0188","BK0010","BK0082","BK0028","BK0250"],"gpt_icon":0},{"id":"2485404116","title":"China Meheco Group Obtains Drug Registration for Antibiotic, Blood Pressure Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=2485404116","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485404116?lang=en_us&edition=full_marsco","pubTime":"2024-11-22 12:27","pubTimestamp":1732249646,"startTime":"0","endTime":"0","summary":"China Meheco Group (SHA:600056) obtained drug registration certificates for clindamycin phosphate and norepinephrine bitartrate injections from China's drug administrator.Clindamycin phosphate is main","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0010","BK0175","600056","BK0028","BK0250","BK0185","BK0082"],"gpt_icon":0},{"id":"2483089927","title":"China Meheco Group Passes Generic Drug Quality Evaluation for Antibiotic; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483089927","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483089927?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 11:27","pubTimestamp":1731554858,"startTime":"0","endTime":"0","summary":"China Meheco Group (SHA:600056) said subsidiary Sanyo Pharmaceutical's cefuroxetine sodium for injection passed the generic drug quality and efficacy consistency evaluation.Cefuroxetine is a cephalosp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0082","BK0188","BK0250","BK0175","BK0185","BK0010","BK0028","600056"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","stockEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0577},{"period":"6month","weight":-0.1021},{"period":"1year","weight":-0.0281},{"period":"ytd","weight":-0.0577}],"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","perCapita":"9752股","boardName":"批发业","registeredCapital":"149587万元","compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0048},{"period":"6month","weight":-0.0002},{"period":"1year","weight":0.0969},{"period":"ytd","weight":-0.0048}],"survey":"　　中国医药健康产业股份有限公司建立了以国际贸易为引领、以医药工业为支撑、以医药商业为纽带的贸、工、技、服一体化产业格局，全面推动工商贸三大业务板块业务整合，积极发挥协同优势。主要产品有原料药、制剂药、中成药、医药商业、国际贸易。公司在中国物流与采购联合会医疗器械供应链分会发布的“2023年中国医疗器械供应链百强企业”中位列第5位；在“2023年中国医疗器械SPD运营服务商重点企业”中位列第11位。","serverTime":1743451293033,"listedPrice":7.02,"stockholders":"153324人(较上一季度减少3.74%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"China Meheco Group Co.,Ltd.(600056),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest China Meheco Group Co.,Ltd.(600056) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"China Meheco Group Co.,Ltd.,600056,China Meheco Group Co.,Ltd.股票,China Meheco Group Co.,Ltd.股票老虎,China Meheco Group Co.,Ltd.股票老虎国际,China Meheco Group Co.,Ltd.行情,China Meheco Group Co.,Ltd.股票行情,China Meheco Group Co.,Ltd.股价,China Meheco Group Co.,Ltd.股市,China Meheco Group Co.,Ltd.股票价格,China Meheco Group Co.,Ltd.股票交易,China Meheco Group Co.,Ltd.股票购买,China Meheco Group Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"China Meheco Group Co.,Ltd.(600056),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest China Meheco Group Co.,Ltd.(600056) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction